Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
La Jolla Pharmaceutical Co.
Headquarters: San Diego, CA, United States of America
Website: N/A
Year Founded: 1989
Status: Acquired
BioCentury | Feb 14, 2023
Market Access
How a narrow FDA label could smooth rezafungin’s launch
Cidara’s antifungal has backing of FDA panel for a limited use indication that homes in on the unmet need
BioCentury | Jul 12, 2022
Finance
July 11 Quick Takes: Qiming announces $3.2B in new venture funds
Plus Innoviva buying La Jolla in diversification push and updates from Novo Nordisk, Genentech, Sanofi, Alnylam and more
BioCentury | Jun 3, 2022
Management Tracks
AbbVie’s Severino joins Flagship’s Tessera as CEO
Plus new CFO, CMO at Renibus, and updates from Bayer, Gilead, Shionogi and more
BioCentury | Mar 5, 2022
Management Tracks
Entos builds out team with Chen as CMO, Ding as CBO
Plus Henderson becomes CEO of Wren, and updates from Bolt, argenx and more
BioCentury | Sep 23, 2021
Product Development
Sept. 22 Quick Takes: Sanofi, two others sought Kadmon deal
Clover readies COVID vaccine for submission, plus Veklury, Xalkori, Hexagon, Paige, Astellas, Rhythm
BioCentury | Sep 15, 2021
Management Tracks
Skullerud named CEO at Nordic Nanovector
Plus: Pyxis, ViaCyte, Neogene, AltruBio, Lyra and more
BioCentury | Aug 1, 2020
Management Tracks
Nabel leaves Moderna’s board to avoid conflict-of-interest concerns; plus changes at Genespire, La Jolla, Editas and more
BioCentury | Jul 18, 2020
Management Tracks
Genzyme vet Modur joins Zikani; plus Scholar Rock, Poseida, Ribon, Kiadis and more
BioCentury | Jun 25, 2020
Deals
June 24 Quick Takes: CSL pays $450M for uniQure’s hemophilia gene therapy; plus Merck-Yumanity, Editas, Compass-Olivia, Century-Empirica, Tetraphase-La Jolla
BioCentury | May 28, 2020
Product Development
May 27 Quick Takes: EC approves Zeposia in RRMS; plus Dupixent approved in children, La Jolla, Shionogi, Alnylam and Bold
Items per page:
1 - 10 of 207